AbbVie Inc. (ABBV)
Pharmaceutical Preparations · Pharmaceutical Preparations · NYSE
$258.94
+3.44%
Investingg Score
50.3 / 100
Hold
Business overview
- Operating margin of 24.6%
- Free cash flow margin of 29.1%
- Sector classified as Pharmaceutical Preparations
These efficiency and margin metrics indicate robust core operations and strong cash conversion capabilities.
Financial health
- Operating margin stands at 24.6%
- Free cash flow margin is reported at 29.1%
- Balance sheet pillar score is 46 out of 100
Together, these figures reflect healthy cash generation relative to operations, though specific leverage details remain unmeasured in the dataset.
- Gross Margin
- Data unavailable
- Operating Margin
- 24.6%
- Current Ratio
- 0.7x
- Debt / Equity
- -19.73
- Free Cash Flow (TTM)
- $17.8B
- Interest Coverage
- 5x
Valuation
- Price-to-sales ratio of 0
- Valuation pillar score of 53 out of 100
- P/E ratio and EV to EBITDA are Data unavailable.
Limited standard valuation metrics in the dataset introduce uncertainty regarding whether the shares are fairly priced at current levels.
- P/E (TTM)
- Data unavailable
- Forward P/E
- Data unavailable
- Price / Sales
- 0.0x
- EV / EBITDA
- Data unavailable
- FCF Yield
- Data unavailable
Key risks
- Earnings per share growth year-over-year declined by 1.3%, signaling bottom-line pressure.
- Multiple key valuation metrics such as P/E ratio and EV to EBITDA are unavailable, creating valuation uncertainty.
- The financial quality pillar score of 37 and balance sheet score of 46 point to potential structural weaknesses.
Market cap $0 · data as of 2026-08-18
Get the full interactive report
Technicals, earnings history, news, bull/base/bear scenarios, Ask the Stock, and more — free to start.
Analyze ABBV with Investingg AINot investment advice. Investingg AI summarizes public data and AI-generated analysis for informational purposes only.